Search Clinical Trials
Completed
Biomarker Guided Therapies in Stage A/B Heart Failure (External Link)
Recently the investigators have shown that HF risk prediction can be improved using cardiac troponin T measured with a novel high-sensitivity assay (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Furthermore, …
Baylor Role:
Collaborator
Completed
Sequential and Hybrid Therapies for H Pylori Infection (External Link)
The purpose of this study is to test whether the 14-day sequential therapy ( esomeprazole plus amoxicillin dual therapy for 7 days followed by triple therapy with esomeprazole, clarithromycin, and …
Baylor Role:
Collaborator
Completed
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection (External Link)
The purpose of this study is to compare different methods of giving combination drug therapy for treating Helicobacter pylori infection of the stomach. The entire study will last less than …
Baylor Role:
Collaborator
Completed
Novel Treatment for Diastolic Heart Failure in Women (External Link)
Subjects with diastolic heart failure defined based on clinical symptoms, echocardiography diastology parameters and brain natriuretic peptide level will be randomized in a 1:1 fashion to either placebo or spironolactone …
Baylor Role:
Lead Sponsor
Completed
Comparison of Sirolimus and Azathioprine in Lung Transplantation (External Link)
This multicenter prospective, randomized controlled clinical trial compared the open label use of sirolimus with that of azathioprine in a tacrolimus-based immunosuppression regimen. Eligible patients were identified during a 90-day …
Baylor Role:
Collaborator
Completed
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome (External Link)
PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by oral spironolactone. Each treatment is administered daily for 6 weeks, with a 6-week washout between drugs. Patients and controls …
Baylor Role:
Collaborator